MedXY News - genomic profiling

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Clinical Updatesbiomarkersgenomic profiling

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY|Mar 6, 2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial

genomic profiling

Latest news

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

Beyond Standard Staging: A Novel Genetics-Based Model Refines Prognosis for AML Patients Treated with Venetoclax and Hypomethylating Agents

Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors

Genomically Matched Therapy Improves Response and PFS Across Advanced Solid Tumors: Phase 2 ROME Trial

Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling